Bacil Pharma Ltd (BACPHAR) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Bacil Pharma Ltd on NSE and BSE, with an AI summary of each filing.
Intimation regarding execution of Agreement by Wholly Owned Subsidiary of the Company
Others (Uncategorized) · 05 Nov 2026, 12:04 am
Bacil Pharma Subsidiary Signs ₹35 Crore R&D Agreement with Efdee Pharma Bacil Pharma Limited announced that its wholly owned subsidiary, Bacil Research and Development Private Limited, entered into an R&D agreement with Efdee Pharma Private Limited on 4th Nov'26. The project focuses on research and development activities for pharmaceutical products, covering pellets, granules, powders, tablets, and capsules. The total estimated cost of the project is ₹35.00 crore.
Un-Audited Financial Results for the Quarter and Half Yearly Ended 30th September, 2026
Financial Result · 14 Oct 2026, 9:46 pm
Bacil Pharma Reports Q2 FY27 Loss of Rs 7.22 Lakh Amid Operational Inactivity Bacil Pharma reported nil revenue from operations for Q2 ended 30th Sep'26, relying entirely on other income of Rs 9.18 lakh (up 3.0% QoQ). Consolidated net loss widened to Rs 7.22 lakh versus a loss of Rs 1.61 lakh in Q1 ended 30th Jun'26, heavily impacted by deferred tax expenses of Rs 4.23 lakh and finance costs of Rs 6.24 lakh. Basic and diluted EPS stood at Rs 0.06. Total consolidated assets stood at Rs 3,081.30 lakh, supported by current borrowings of Rs 552.24 lakh.
Outcome of Board Meeting held on 14th October, 2026
Outcome · 14 Oct 2026, 9:41 pm
Bacil Pharma Reports Q2 Standalone Net Loss of ₹0.98 Lakh Bacil Pharma reported zero operational revenue for the quarter ended 30th Sep'26, generating ₹9.18 lakh in other income compared to ₹8.91 lakh in the previous quarter. On a standalone basis, net loss after tax narrowed to ₹0.98 lakh from a loss of ₹1.61 lakh in the quarter ended 30th Jun'26, while total comprehensive income stood at ₹15.29 lakh. Consolidated net loss widened to ₹7.22 lakh. For the half year ended 30th Sep'26, total income fell sharply to ₹18.09 lakh from ₹105.74 lakh YoY.
Intimation for resignation of Company Secretary
Change in Management · 09 Oct 2026, 1:04 am
Bacil Pharma Whole-Time Company Secretary Resigns Bacil Pharma Limited announced the resignation of Mr. Dikshant Singh Panwar from the position of Whole-Time Company Secretary and Compliance Officer, effective 8th Oct'26. The resignation was tendered citing increasing personal and professional commitments requiring dedicated attention. The company's board has accepted his resignation and initiated the process to appoint a suitable successor for the role of Company Secretary and Compliance Officer in compliance with the Companies Act, 2013 and SEBI LODR Regulations.
Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/10/2026 ,inter alia, to consider and approve 1. Unaudited Financial Results ....
Intimation · 14 Oct 2026, 5:30 am
Bacil Pharma Schedules Board Meeting for Q2 FY27 Financial Results Bacil Pharma Limited has informed BSE that a meeting of its Board of Directors is scheduled for 14th Oct'26. The board will primarily consider and approve the unaudited financial results of the company for the quarter and half-year ended 30th Sep'26, alongside addressing any other business matters permitted by the Chairperson.
Scrutinizers Report for the Annual General Meeting of the Company for FY 2025-2026
Annual General Meeting · 24 Sept 2026, 9:04 pm
Outcome/Proceeding of Annual General Meeting of the Company
Annual General Meeting · 23 Sept 2026, 10:54 pm
Annual Report for the Financial Year 2025-2026
Others (Uncategorized) · 31 Aug 2026, 6:35 pm
Notice of Annual General Meeting to be held on 23rd September, 2026
Annual General Meeting · 30 Aug 2026, 5:16 am
Outcome of Board Meeting held on 29th August, 2026
Outcome · 29 Aug 2026, 6:51 pm
Bacil Pharma to Seek Shareholder Nod for Capital Raise and MD Appointment Bacil Pharma's Board approved holding its 39th AGM on 23rd Sep'26. Key agenda items include seeking shareholder approval for an increase in authorized share capital from Rs. 20 crore to Rs. 70 crore. The company will also seek to confirm the change in designation of Ms. Chaitali Kalpataru Shah from Executive Director to Managing Director, effective from 25th Aug'26, for a five-year term. Other proposals include the appointment of new directors and the re-appointment of Sarang Shivajirao Chavan & Associates as statutory auditors.
Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/08/2026 ,inter alia, to consider and approve Discussion on Notice for 39th ....
Intimation · 27 Aug 2026, 12:12 am
Appointment of Director
Others (Uncategorized) · 25 Aug 2026, 10:22 pm
Bacil Pharma Appoints Two New Directors to Strengthen Board Bacil Pharma Limited's board, on 25th Aug'26, approved the appointment of two Additional Directors. Mr. Mahesh Singh joins as a Non-Executive Independent Director, bringing over seven years of trading industry experience to enhance accounting and financial expertise. Mr. Anil Shiv Charan Singh is appointed as a Non-Executive Director to leverage his business management and commodity trading experience. Both appointments are subject to member approval and aim to strengthen the board's strategic capabilities and business development.
Outcome of Board Meeting held on 25th August, 2026
Outcome · 25 Aug 2026, 10:20 pm
Bacil Pharma Strengthens Board with Two New Director Appointments Bacil Pharma's board approved two key appointments on 25th Aug '26. Mr. Mahesh Singh was appointed as a Non-Executive Independent Director to leverage his 7+ years of experience in the trading industry, product sales, and financial matters. Additionally, Mr. Anil Shiv Charan Singh was appointed as a Non-Executive Director to bring his expertise in business management, commercial activities, and commodity trading. Both appointments are subject to member approval and aim to enhance the Board's strategic and financial capabilities.
Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/08/2026 ,inter alia, to consider and approve Board meeting to be held on 25th ....
Intimation · 18 Aug 2026, 4:24 am
Bacil Pharma Board Meeting Scheduled to Discuss Director Appointments Bacil Pharma Ltd. (BSE: 524516) has scheduled a Board of Directors meeting for 25th Aug'26. The primary agenda item is to discuss and consider the appointment of new directors. This key meeting follows the company's intimation to the stock exchange on 17th Aug'26, as per SEBI's listing regulations. Any potential changes to the board composition will be a key outcome for investors to monitor.
Un-audited Financial Results for the Quarter Ended 30th June, 2026
Financial Result · 12 Aug 2026, 9:48 pm
Bacil Pharma Reports Q1FY27 Results; Revenue Plummets YoY Bacil Pharma reported Q1FY27 results ending 30-Jun'26, showing a sharp revenue decline to ₹8.91 lakh from ₹100.30 lakh YoY. Total profit for the period stood at ₹30.12 lakh, a 55% YoY decrease from ₹66.90 lakh, but a recovery from a loss of ₹164.14 lakh QoQ. The profit figure was significantly boosted by a ₹31.73 lakh gain on fair valuation of financial assets. Basic EPS fell to ₹0.22 from ₹0.48 YoY. The board approved the unaudited results on 12-Aug'26.
Outcome of Board Meeting held on 12th August, 2026
Outcome · 12 Aug 2026, 9:43 pm
Bacil Pharma Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 0.0 ■ EBITDA: -2.3 (+79.2% YoY | +69.5% QoQ) ■ EBITDA Margin (%): 0.0 ■ PAT: 30.1 (-55.0% YoY | Loss to Profit QoQ) ■ EPS (INR): 0.22 (-54.2% YoY | -50.0% QoQ)
Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Intimation of Board Meeting for ....
Intimation · 12 Aug 2026, 5:30 am
Bacil Pharma Board Meeting on 12th Aug'26 for Q1FY27 Results Bacil Pharma Limited (BSE: 524516) announced a Board of Directors meeting scheduled for 12th Aug'26. The primary agenda is to consider and approve the unaudited financial results for the first quarter ending 30th Jun'26. This meeting will set the financial performance baseline for the new fiscal year.
Regarding the incorporation of a wholly owned subsidiary of the company named Bacil Research & Development Private Limited.
Others (Uncategorized) · 29 Jul 2026, 12:01 am
Bacil Pharma Incorporates New Wholly-Owned R&D Subsidiary Bacil Pharma Limited (BSE: 524516) announced it has incorporated a new wholly-owned subsidiary, Bacil Research & Development Private Limited, on 28th Jul'26. This strategic move formalizes the company's focus on research and development activities through a dedicated entity. The incorporation aligns with the firm's objective to expand its R&D capabilities. Further details are awaited regarding the new subsidiary's specific operational scope and financial structure.
Attached Resignation of Directors as Query raised from BSE
Others (Uncategorized) · 18 Jul 2026, 6:50 pm
Bacil Pharma Board Approves ₹50 Crore Rights Issue and Capital Increase Bacil Pharma's board, on 09th Jul'26, approved a proposal to raise up to ₹50 crore through a rights issue. To facilitate this, the board also approved increasing the authorised share capital by ₹45 crore, bringing the new total to ₹65 crore, subject to shareholder approval. Concurrently, the company announced the resignations of two Independent Directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, effective 09th Jul'26, citing personal preoccupations and other engagements.
Attached Resignation of Directors as query raised from BSE
Change in Management · 10 Jul 2026, 8:54 pm
Bacil Pharma Board Approves ₹50 Crore Rights Issue and Capital Increase The Board of Bacil Pharma on 9th Jul'26 approved raising funds up to ₹50 crore via a Rights Issue. To facilitate this, the board also approved increasing the authorized share capital by ₹45 crore to a total of ₹65 crore, subject to shareholder approval. A Right Issue Committee has been formed to oversee the process. Additionally, the board accepted the resignations of two Independent Directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, effective 9th Jul'26, citing personal preoccupations.
As Per Announcement
Change in Management · 10 Jul 2026, 1:37 am
Bacil Pharma Board Approves ₹50 Crore Rights Issue and Capital Increase Bacil Pharma's board, on 9th Jul'26, approved raising up to ₹50 crore via a rights issue of equity shares. To facilitate this, the board also approved increasing the authorised share capital by ₹45 crore to a total of ₹65 crore, subject to shareholder approval. The company formed a Rights Issue Committee to determine the issue's terms, including price and ratio. Additionally, the board noted the resignation of two independent directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya.
As Per Announcement
Others (Uncategorized) · 10 Jul 2026, 1:36 am
Bacil Pharma Board Approves ₹50 Crore Rights Issue and Capital Increase Bacil Pharma's board, on 9th Jul'26, approved a proposal to raise up to ₹50 crore via a rights issue of equity shares. To facilitate this, the board also approved increasing the authorised share capital by ₹45 crore to a new total of ₹65 crore, subject to shareholder approval. A Right Issue Committee has been formed to determine the terms, including price and ratio. Concurrently, the board approved the resignation of two Independent Directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya.
As Per Announcement
Outcome · 10 Jul 2026, 1:35 am
Bacil Pharma Board Approves ₹50 Cr Rights Issue and Capital Increase Bacil Pharma's board, on 09 Jul'26, approved fundraising up to ₹50 crore via a rights issue. To facilitate this, the board also greenlit an increase in authorised share capital by ₹45 crore to ₹65 crore. The company has appointed intermediaries including Axis Bank as the banker to the issue. Terms such as issue price and record date will be decided later. Additionally, the board noted the resignation of two Independent Directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya.
Intimation regarding Approval of Name for Proposed Wholly-owned Subsidiary
Others (Uncategorized) · 08 Jul 2026, 12:46 am
Bacil Pharma Receives Name Approval for New R&D Subsidiary Bacil Pharma Limited announced on 7th Jul'26 that the Ministry of Corporate Affairs has approved the name for its proposed wholly-owned subsidiary, "Bacil Research & Development Private Limited." The approval, valid until 26th Jul'26, marks a key step in the subsidiary's incorporation process. The company stated that the full incorporation is currently underway, with further disclosures to be made upon receiving the Certificate of Incorporation. This move signals an expansion of the company's focus on research and development activities.
Bacil Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/07/2026 ,inter alia, to consider and approve 1. The proposal for raising funds ....
Intimation · 04 Jul 2026, 12:23 am
Bacil Pharma to Consider ₹50 Crore Rights Issue on 9th Jul'26 Bacil Pharma's Board will meet on 9th Jul'26 to consider and approve a proposal for raising funds up to ₹50 crore via a rights issue of equity shares. The agenda also includes a potential increase in the authorised share capital to facilitate the issue. The board will determine the detailed terms, including issue size, entitlement ratio, price, and record date. Discussions on the appointment and resignation of directors are also scheduled. The trading window remains closed for designated persons until 48 hours after the meeting's outcome.